Newron Pharmaceuticals SpA is a leading pharmaceutical company that represents a strong set of values and a dedicated corporate philosophy. With a commitment to innovation and the improvement of patients' lives, Newron focuses on developing novel therapeutic solutions. Their core values include integrity, accountability, and a patient-centric approach. By combining cutting-edge research, state-of-the-art technologies, and a highly skilled team, Newron strives to bring effective treatments to the market. The company's dedication to ethical practices, scientific excellence, and collaboration with key stakeholders further reinforces its mission of making a positive impact in the field of pharmaceuticals.

Newron Pharmaceuticals SpA is primarily present in Europe, with a focus on countries such as Italy, Germany, France, and Switzerland. Additionally, the company has a presence in the United States. As a leading pharmaceutical company, Newron Pharmaceuticals SpA operates globally, engaging in research, development, and commercialization of novel therapies for neurological disorders. By expanding its reach in strategic markets, including Europe and the United States, Newron Pharmaceuticals SpA aims to enhance patient access to its innovative products and address the unmet medical needs of individuals living with neurological conditions.

Newron Pharmaceuticals SpA has achieved several significant milestones. One notable accomplishment includes the successful completion of a Phase III clinical trial for their lead product, Xadago®, a treatment for Parkinson's disease. Additionally, the company has received approval for Xadago® from regulatory authorities in both the European Union and the United States. Newron Pharmaceuticals SpA has also established partnerships with global pharmaceutical companies to further develop and commercialize their innovative drug pipeline. Moreover, the company continues to focus on advancing research and development efforts to bring new treatments to patients in need.

Newron Pharmaceuticals SpA is a renowned pharmaceutical company that specializes in developing innovative therapies for patients suffering from diseases of the central nervous system. Established in 1999, Newron Pharmaceuticals SpA has shown consistent dedication towards advancing neuroscience research and providing effective treatment options. Over the years, the company has successfully built a strong foundation in the fields of neurology and psychiatry. Notably, Newron Pharmaceuticals SpA has focused on developing drugs that target unmet medical needs, particularly in rare neurological and psychiatric disorders. Through continuous research and development, Newron Pharmaceuticals SpA aims to improve the lives of patients worldwide.

The main competitors of Newron Pharmaceuticals SpA in the market include XYZ Pharmaceuticals, ABC Biotech, and DEF Therapeutics.

Newron Pharmaceuticals SpA primarily operates in the pharmaceutical industry.

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development and commercialization of novel therapies for patients with diseases of the central nervous system. Their business model revolves around identifying high unmet medical needs and developing innovative treatments to address them. Newron leverages its scientific expertise to research, test, and seek regulatory approval for new drugs, aiming to improve the quality of life for patients suffering from neurological disorders. By combining scientific advancements and strategic partnerships, Newron Pharmaceuticals SpA aims to bring these innovative therapies to market, ultimately creating value for its shareholders and contributing to the healthcare industry.

Newron Pharmaceuticals SpA의 P/E 비율은 -6.07입니다.

Newron Pharmaceuticals SpA의 P/S 비율은 13.59입니다.

Newron Pharmaceuticals SpA에 대한 AlleAktien 품질 점수는 7/10입니다.

예상되는 Newron Pharmaceuticals SpA 매출은 12.19 백만 EUR입니다.

예상되는 Newron Pharmaceuticals SpA 이익은 -27.28 백만 EUR입니다.

Newron Pharmaceuticals is a biopharmaceutical company based in Milan, Italy, specializing in researching and developing novel therapies for central nervous system diseases. The company has three main divisions: research and development, manufacturing, and distribution. It has a strong pipeline of drug candidates in various stages of clinical development, with a focus on neurology and psychiatry. Newron Pharmaceuticals aims to provide innovative treatment options for patients with neurological diseases and expand its global market presence. The company's current products include Xadago, used for Parkinson's disease, and Sarizotan, being developed for Rett syndrome. Newron Pharmaceuticals aims to improve the quality of life for patients with neurological disorders through its research and development efforts. Its business model is centered around addressing the unmet needs of these patients and collaborating with other pharmaceutical companies for product development and marketing. The company is well-positioned to advance in the field of central nervous system research and meet the demands of patients with neurological diseases.

Newron Pharmaceuticals SpA은(는) 연간 번의 배당을 통해 0 EUR의 배당금을 지급합니다.

Newron Pharmaceuticals SpA의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Newron Pharmaceuticals SpA의 ISIN은 IT0004147952입니다.

Newron Pharmaceuticals SpA의 WKN은 A0LF18입니다.

Newron Pharmaceuticals SpA의 티커는 NWRN.SW입니다.

지난 12개월 동안 Newron Pharmaceuticals SpA은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Newron Pharmaceuticals SpA은(는) 0 EUR의 배당금을 지급할 것으로 예상됩니다.

Newron Pharmaceuticals SpA의 현재 배당 수익률은 입니다.

Newron Pharmaceuticals SpA은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Newron Pharmaceuticals SpA은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 EUR의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Newron Pharmaceuticals SpA은 '건강' 섹터에 속합니다.

Newron Pharmaceuticals SpA의 마지막 배당금을 0 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Newron Pharmaceuticals SpA는 0 EUR를 배당금으로 지급했습니다.

Newron Pharmaceuticals SpA의 배당금은 EUR에 지급됩니다.